Govt. improving healthcare and medical education through holistic approach: Dr. Mandaviya

Investment proposals to the tune of Rs. 54,000 crore has been received in the healthcare and Rs. 17,000 crore has been received in medical education sector

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK

US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease

The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial

G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul

There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare

ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology

The new project further expands the partner's long-term collaboration on new technologies for R&D

Cipla EU to invest € 15 million in Ethris

Cipla and Ethris partner for the development of mRNA-based therapies

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Synchron raises $75 mn Series C Led by ARCH Venture Partners

Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors

Torrent enters into co-marketing partnership with Boehringer Ingelheim India

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.